Press Release: Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis
Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosisResults from the HERCULES phase 3 ...
The New England Journal of Medicine1h
Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis
Throughout the course of multiple sclerosis, gradually progressive neurologic impairment can occur, which has been called ...
The New England Journal of Medicine1h
Tolebrutinib versus Teriflunomide in Relapsing Multiple Sclerosis
Tolebrutinib is an oral, brain-penetrant, and bioactive Bruton’s tyrosine kinase inhibitor that modulates peripheral ...
The Manila Times1h
Maple Tree Counselling And Therapy Practice Hong Kong Announces Top Mental Health Program For Corporate Employees In HK
Central, April 08, 2025 (GLOBE NEWSWIRE) -- Central, Hong Kong - ...
New therapeutic targets discovered for multiple sclerosis tissue recovery
Researchers from the Netherlands Institute for Neuroscience (NIN) have discovered new potential therapeutic targets for multiple sclerosis (MS). While current treatments prevent further damage, the ...
Trial is the first to show a delay in confirmed disability progression in non-relapsing secondary progressive MS
A Cleveland Clinic-led clinical trial of tolebrutinib, an investigational oral Bruton's tyrosine kinase inhibitor, a group of ...
Mirage News2h
Cleveland Clinic Trial Delays Disability in MS Patients
Cleveland: A Cleveland Clinic-led clinical trial of tolebrutinib, an investigational oral Bruton's tyrosine kinase inhibitor ...
Science Daily6h
AI tool can track effectiveness of multiple sclerosis treatments
A new artificial intelligence (AI) tool that can help interpret and assess how well treatments are working for patients with multiple sclerosis (MS) has been developed.
Live Science2d
$3 million Breakthrough Prize goes to scientists that completely changed our understanding of multiple sclerosis
Two prominent scientists who study multiple sclerosis — Dr. Alberto Ascherio and Dr. Stephen Hauser — are co-winners of a ...
Multiple Sclerosis News Today3d
Study confirms approved Ocrevus dose as optimal for relapsing MS
No added benefits in slowing MS disability progression were found in a study that increased Ocrevus dosing to 2-3 times the ...
Healio3d
Tolebrutinib slows disability accumulation in secondary progressive multiple sclerosis
Treatment with tolebrutinib led to greater confirmed disability improvement at 6 months compared with placebo in patients ...